All In Biotech

Drug Trial Radar · NCT00624780

Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder

Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder

Last checked: Nov 19, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 615 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

615

Actual

Start

May 2009

Primary completion

Apr 2012

Study completion Apr 2012

Sponsor

Sponsor type
Industry
First posted
Feb 27, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety and efficacy in patients with generalized anxiety disorder after short- (3 months) and long-term (6 months) use of Pregabalin (Lyrica).

Conditions

  • Generalized Anxiety Disorder

Interventions

  • PregabalinDrug

    Pregabalin 150-300 mg given twice a day

  • LorazepamDrug

    Lorazepam 3-4 mg given twice a day

  • PregabalinDrug

    Pregabalin 450-600 mg given twice a day

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
  2. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
  3. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
  4. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
  5. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
  6. Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
  7. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
  8. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
  9. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
  10. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
  11. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
  12. Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)

Locations

57 sites in 16 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Buenos Aires, Argentina

  • Pfizer Investigational Site

    Buenos Aires, Argentina

  • Pfizer Investigational Site

    Buenos Aires, Argentina

  • Pfizer Investigational Site

    La Plata, Buenos Aires, Argentina

  • Pfizer Investigational Site

    Lanus, Prov. de Buenos Aires, Argentina

  • Pfizer Investigational Site

    Vienna, Austria

  • Pfizer Investigational Site

    Vienna, Austria

  • Pfizer Investigational Site

    San José, Costa Rica

  • Pfizer Investigational Site

    San José, Costa Rica

  • Pfizer Investigational Site

    Rijeka, Croatia

  • Pfizer Investigational Site

    Split, Croatia

  • Pfizer Investigational Site

    Zagreb, Croatia

  • Pfizer Investigational Site

    Brno, Czechia

  • Pfizer Investigational Site

    České Budějovice, Czechia

  • Pfizer Investigational Site

    Litoměřice, Czechia

  • Pfizer Investigational Site

    Lnáře, Czechia

  • Pfizer Investigational Site

    Mělník, Czechia

  • Pfizer Investigational Site

    Prague, Czechia

  • Pfizer Investigational Site

    Prague, Czechia

  • Pfizer Investigational Site

    Praha 10- Strasnice, Czechia

  • Pfizer Investigational Site

    Strakonice, Czechia

  • Pfizer Investigational Site

    Espoo, Finland

  • Pfizer Investigational Site

    HUS, Finland

  • Pfizer Investigational Site

    Joensuu, Finland

  • Pfizer Investigational Site

    Kuopio, Finland

  • Pfizer Investigational Site

    Seinäjoki, Finland

  • Pfizer Investigational Site

    Turku, Finland

  • Pfizer Investigational Site

    Athens, Greece

  • Pfizer Investigational Site

    Ellisbridge, Ahmedabad, India

  • Pfizer Investigational Site

    Tirupati, Andhra Pradesh, India

  • Pfizer Investigational Site

    Mangalore, Karnataka, India

  • Pfizer Investigational Site

    Pune, Maharashtra, India

  • Pfizer Investigational Site

    Chennai, Tamil Nadu, India

  • Pfizer Investigational Site

    Surabaya, Indonesia

  • Pfizer Investigational Site

    Denpasar, Bali, Indonesia

  • Pfizer Investigational Site

    Jakarta, Jakarta Selatan, Indonesia

  • Pfizer Investigational Site

    Jakarta Selatan, Jakarta Special Capital Region, Indonesia

  • Pfizer Investigational Site

    Kaunas, Lithuania

  • Pfizer Investigational Site

    Kaunas, Lithuania

  • Pfizer Investigational Site

    Klaipėda, Lithuania

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.